Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4817 Comments
1656 Likes
1
Wilva
New Visitor
2 hours ago
I read this and now I feel stuck.
👍 67
Reply
2
Solas
Elite Member
5 hours ago
This feels like a warning I ignored.
👍 274
Reply
3
Auttum
Engaged Reader
1 day ago
Oh no, should’ve seen this sooner. 😩
👍 279
Reply
4
Lalit
Trusted Reader
1 day ago
Broad indices continue to trend higher with manageable risk.
👍 105
Reply
5
Cailley
Legendary User
2 days ago
There has to be a community for this.
👍 170
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.